A tight association has been identified between NAFLD and T2D; as such, several anti-diabetic drugs, such as glucagon-like peptide-1 receptor agonists, thiazolidinedione insulin sensitizers, and sodium/glucose cotransporter-2 inhibitors, have been the subject of clinical trials for NAFLD and have shown potential for improving the outcomes in patients with NAFLD, both with and without comorbid T2D [82]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.